From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

SkinBioTherapeutics – no-one watching o’clock results and equity raise, what’s the outlook from here?

By Tom Winnifrith & Steve Moore | Saturday 17 December 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

SkinBioTherapeutics (SBTX) has announced no-one watching o’clock (4:30pm) results for its year ended 30th June 2022, with CEO Stuart Ashman stating “this financial year has been a mixed one for the group”. With the results coming with a potentially £3.5 million equity raise (albeit including an up to £1 million “retail offer”) at 16p per share, we’ve got some other words for it but where does this all leave the company now?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



H&T Group – now again a Buy

Time left: 04:29:40